William Sanger's questions to Intellia Therapeutics Inc (NTLA) leadership • Q1 2025
Question
William Sanger, on behalf of Mani Faroohar, asked for more detail on expected cash burn and operating expenses over the next 12-24 months, particularly regarding any notable non-recurring costs from the recent restructuring.
Answer
Chief Financial Officer Ed Dulac projected an average quarterly cash use of approximately $95 million for 2025 and 2026. He explained that Q1 2025 cash use was higher due to $51 million in non-recurring costs for severance and real estate transactions, which he noted are part of a cash-neutral plan expected to yield nearly $50 million in future savings. The current cash runway is sufficient into the first half of 2027.